Thirteen new rare gene variants in loci related to synaptic function and neuronal development were associated with Alzheimer’s disease. (Alzheimer’s and Dementia)
In an unusual JAMA op-ed, three members of the FDA’s advisory committee reviewing aducanumab took another shot at the controversial Alzheimer’s drug candidate, laying out reasons why aducanumab shouldn’t be approved.
The FDA rejected Acadia Pharmaceuticals’ bid to expand indications for pimavanserin (Nuplazid) to include hallucinations and delusions associated with dementia-related psychosis. The notice came a month after the agency first alerted the company to potential snags with its application.
